Taking stock of the drug industry, from the lab to the medicine chest

March 13, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kayla Bartkowski/Getty Images Trump's picks to run FDA and NIH win approval from Senate's health committee Jay Bhattacharya, nominee for National Institutes of Health director, and FDA pick Marty Makary clear key Senate committee. By Sarah Owermohle and Lizzy Lawrence STAT+ | Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein's lab Cage Pharma executives say they see promise in the therapy — 3-bromopyruvate or 3BP — despite a troubled history. By Allison DeAngelis STAT+ | In the Boston area, biotech's hub, a slump is being acutely felt Stocks are down, the industry is grappling with excess lab space, and hiring remains soft, with many biopharma companies continuing to lay off workers. By Robert Weisman — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser